Validation of Altered MiRNAs in Ovarian Cancer Tumors”

Creative Commons License

Tekaraslan E. E., Günel T., Gümüşoğlu E., Hosseini M. K., Çevik N., Topuz S., ...More

1st International Symposium on Graduate Research in Science, İstanbul, Turkey, 4 - 06 October 2018, vol.26, no.1, pp.10

  • Publication Type: Conference Paper / Summary Text
  • Volume: 26
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.10
  • Istanbul University Affiliated: Yes


Epithelial ovarian cancer (EOC) is the second most important cause of cancer-related

deaths among women worldwide. Due to the mild and common symptoms of EOC, the

disease can not be diagnosed at an early stage. Survival rate in ovarian cancer (OC)

patients is limited to over 80%. When the disease spreads to the upper abdomen or

other parts of the body (stage III and IV), only 20% of the patients survive for 5 years.

Currently, diagnostic methods for EOC are pelvic examination, transvaginal

ultrasonography (TVS) and serum cancer antigen 125 (CA125), however EOC can not

be diagnosed at early stages. CA125 is the only serum biomarker routinely used for

epithelial ovarian cancer and gives 99% certainty, but in postmenopausal women

sensitivity to early disease is only 50-60%[1]. Therefore, finding a reliable biomarker

with increased sensitivity to early stages of epithelial ovarian cancer remains an

important clinical problem.

MicroRNAs (miRNAs) are a class of small non-coding RNAs 18-25 nucleotides in

length. MiRNAs are involved in various biological processes such as cell proliferation,

development, differentiation, apoptosis. MiRNAs display abnormal expression patterns

in different cancer forms. Some act as tumor suppressor genes or oncogenes.

Expression of miRNAs is therefore important in the development of ovarian cancer [2].

Studies have shown that there are differences in miRNA expressions between normal

ovarian epithelial and ovarian cancer epithelial.

Hsa-mir-200c-3p, hsa-mir-4665-3p and hsa-mir-6737-3p expression levels are

upregulated in ovarian cancer tissue to benign cyst samples by microarray results. In

this study, 10 EOC tissue samples and 10 benign cyst samples (BCS) as control were

used and 3 miRNAs expression differences between these 2 groups are validated by

Real-Time PCR method. This project aims to detect biomarkers with transcriptomic

studies in order to extend early 5 years survival time of women with cancer and early

diagnosis of OC.